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Abstract Global access programs (GAPs) provide access
to medicinal products for patients with serious medical
conditions and no commercially available treatment op-
tions. Providing early access to medicines can be chal-
lenging for a pharmaceutical company. The demand for a
GAP often occurs at a time when other activities are the
prime focus, such as delivery of pivotal clinical trials or
gaining of marketing authorization. Furthermore, the skills,
experience, and infrastructure necessary to implement and
manage a successful GAP vary significantly from those
required for regular clinical trial execution, and the
regulatory environment presents its own challenges, with
regulations often poorly defined and with considerable in-
ter-country variation. This article considers the triggers for
early access requests and examines the need for companies
to develop a global strategy for GAPs in order to respond
appropriately to requests for early access. It also provides a
comprehensive overview of the processes for GAP set-up,
implementation, management, and closure, along with the
considerations affecting the type and scope of GAP, such
as demand, regulatory feasibility, license status of the
product, drug pricing structure, company strategy, costs,
and product supply. Also discussed is the need for appro-
priate personnel to implement and manage the GAP, and
when to consider collaboration with an external GAP
provider. In summary, GAPs require careful and efficient
planning and management, from set-up to closure. Well-
run GAPs provide an ethical and regulatory-compliant
pathway for access of new treatments to patients with se-
rious conditions and an unmet medical need.
Key Points
In order to be able to respond to requests for early
access of a drug in a timely manner, companies
should plan to implement a comprehensive strategy
at a global level.
The type and scope of the global access program
(GAP) that is run will depend on considerations such
as demand, regulatory feasibility, the license status of
the product, and necessary drug pricing structure, as
well as company strategy, costs, and product supply.
Successful GAPs require careful and efficient
planning and management, from set-up to closure, by
either an internal coordinating project manager or a
specialist provider.
Throughout the article, we use the term ‘GAP’.
These are often referred to as early access programs,
but we use this as an umbrella term that covers
multiple scenarios including, but not limited to,
where the medicinal product may be completely
unlicensed globally but also where it may be
approved in a major market but is not yet approved
in the country of required supply.
1 Introduction
When patients with a serious medical condition have ex-
hausted all available treatment options and enrollment into
a clinical trial is not a possibility, patients and their
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physicians may consider accessing promising new and
commercially unavailable treatments via a ‘global access
program’ (GAP), on either a single patient or cohort-based
level.
GAPs allow access to medicinal products that are not
commercially available in a patient’s country, e.g., if a
product is in clinical development, is licensed in a country
other than the patient’s own, is licensed but not commer-
cially available, or has been withdrawn.
The demand for GAPs from patients and their carers is
increasing, with high-profile cases in the press and social
media gaining much attention. This trend is likely to con-
tinue as pharmaceutical and biotechnology companies
continue to focus on developing medicines in areas of high
unmet need and as patients and healthcare professionals
monitor product pipelines and developments more closely.
Providing access to medicines that are not commercially
available in a patient’s country can be challenging for
pharmaceutical and biotechnology companies, with con-
fusion and misconceptions about what is and what is not
possible. GAPs differ fundamentally from clinical trials
and some of the differences have been summarized in a
recent publication [1]. The primary focus of a clinical trial
is demonstration of safety and efficacy, whereas a GAP is
focused upon meeting an unmet patient need. Given the
differences between the two, it is not surprising that the
skills, experience, and infrastructure necessary to imple-
ment and manage a successful GAP vary significantly from
those required for clinical trial execution.
Furthermore, the regulatory environment presents its
own challenges, as unlicensed use outside of clinical trials
is governed by different regulations to those covering
clinical trial set-up and delivery (with the exception of
regulations in the USA [2, 3]); regulations are also often
poorly defined, open to interpretation, and vary consider-
ably from country to country outside of the USA. As a
result, companies that have limited experience and practi-
cal knowledge of GAPs can find it difficult to navigate this
complex area.
This article focuses on GAPs run outside of the USA,
although many aspects are equally applicable to the USA.
It examines the triggers for early access requests, how such
requests can be responded to, regulatory considerations,
and the processes for set-up, implementation, management,
and closure of GAPs.
2 Triggers for Early Access Requests
The main trigger for a pharmaceutical or biotechnology
company (the sponsor) to consider implementing a GAP is
the receipt of requests from patients or their physicians.
Requests are often triggered by events or conferences
announcing promising results from clinical trials. They
may also occur when a product receives approval in an-
other country, when patients exiting clinical trials wish to
continue on treatment, or when investigators have patients
that do not meet the eligibility criteria for a trial but still
may benefit from treatment. Requests for early access
generally occur when there is some evidence of safety and
efficacy from phase II/III trials. However, dependent on the
severity of the unmet need, it can be earlier than this, as
demonstrated recently when patients infected with the
Ebola virus were the first human subjects to receive the
experimental ZMapp treatment [4].
3 Response to Early Access Requests:
Development of Company Guidance
A pharmaceutical company should produce a comprehen-
sive, product-specific, country-by-country plan for a GAP,
to implement, manage, and exit the program in each
country. Several previous articles have proposed decision
trees and go/no-go decisions for whether a company should
initiate a GAP [5, 6]. Here, we examine the key elements
that a pharmaceutical company will need to consider in
order to be able to plan and respond appropriately and
efficiently to requests for early access. Regulatory con-
siderations are covered separately in Sect. 4 below.
In order to be able to respond to such requests in a
timely manner, companies should plan to implement a
comprehensive strategy at a global level. This is par-
ticularly relevant for companies involved in the develop-
ment of products in areas of high unmet need, where there
is an absence of approved and commercially available al-
ternative treatments on the market. A company guidance
document or standard operating procedure should include
details of when programs need to be considered (phase in
development, therapy area, patient population), who will be
the decision makers and governance bodies, how and by
whom a program should be implemented, how often indi-
vidual project strategies should be reviewed, and budgetary
considerations. One option is for the global project devel-
opment team to include an access program review at pro-
ject milestones, such as when a product enters
development, and at each clinical milestone thereafter. The
guidance document should provide clear direction for
project teams and be flexible enough to allow adaption for
each particular product and request scenario. Key aspects
to be considered when developing company guidance are
detailed below.
(a) Assignment of global access program (GAP) team
roles and responsibilities
The key decision makers and their roles should be
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identified and the contributions of individual func-
tions, project teams and stakeholders should be
considered. A typical list of those who may need to
be involved is included in Table 1, along with their
anticipated roles in the program.
There will be significant differences in the way that
companies manage GAPs, depending on their size and
organizational structure. Small to mid-size compa-
nies, compared with large pharmaceutical companies,
tend to have simpler governance and decision-making
processes but less in-house experience and resources
for managing a GAP.
Companies with large geographical footprints will
need to consider the role of local affiliates/operating
companies during both the set-up and delivery phases.
These groups may often have strong opinions regard-
ing the activities in their countries; this can potentially
lead to a lack of a coherent global strategy and
inconsistent implementation. On the other hand, the
support of local affiliates may be necessary or
advantageous, e.g., the use of affiliate pharma-
covigilance services. Hence, early engagement is
recommended to ensure that the global strategy is
adopted within the regulations of the particular
country, and that the appropriate level of involvement
of an affiliate is incorporated into the program.
Given the number of decision makers, specialists,
and stakeholders involved, it is strongly recom-
mended that a project manager is appointed, who can
undertake a central role in coordinating and manag-
ing team input. The project manager needs to ensure
that the program is designed, set up, and managed to
meet the objectives of the GAP, as well as managing
any inter-dependencies with other product activities,
such as ongoing clinical trials or marketing autho-
rizations. They should also ensure adequate and
ongoing stakeholder management throughout the
project.
(b) Consideration of collaboration with external GAP
specialist providers
Another key consideration is the organization’s
knowledge of GAPs, and when it may be beneficial
to bring in outside expertise with practical experience,
not only in the context of development of the strategy
and implementation of programs, but also to assist
with training and communication within the organi-
zation, and ongoing management of the program.
While some companies choose to upskill a project
Table 1 Roles of sponsor personnel in global access program planning
Key sponsor personnel Role
Senior management teams Key decision makers regarding the strategy for the implementation of GAPs, particularly concerned with
the impact on the company and its reputation
Procurement/global external sourcing May have significant involvement in GAP partner selection, with a focus on cost and on compliance





Key decision makers in the initiation of GAPs. Some of their main objectives are to:
Ensure the establishment of an effective and efficient GAP process (with consideration of the potential
impact of a GAP on parallel clinical trial recruitment)
Define the process for patient screening and the criteria for eligibility
Implement the necessary training, e.g., for affiliates and prescribers, and plan communications such as
press releases
Regulatory affairs managers Decision makers in GAP design and planning, concerned with compliance with individual country
regulatory requirements and the potential impact of an access program on other regulatory activities
such as marketing authorization applications (EU) or new drug applications (USA)
Market access and brand managers Keen interest in the potential return on investment from running a GAP, and the potential impact on
product launch plans and commercialization, as well as on product price and reimbursement
Pharmacovigilance Consulted regarding plans for patient follow-up and adverse event collection, and will have an ongoing
involvement in the reporting of safety events during the program
Quality compliance personnel May be involved in a number of aspects of the GAP such as pre-selection of supplier to ensure
compliance with company standards, integration of the GAP process into company standard operating
procedures, product labeling and release, recall procedures, validation of shipping routes and
packaging, facilities and licenses, and data protection
Chemistry manufacturing controls
and supply chain
Consulted for information around the availability of the product, labeling and qualified person
requirements, and changes in product presentation throughout the program
GAP global access program
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manager internally to act as a central point of
knowledge regarding GAPs, others may choose to
use external specialist providers to provide the
detailed knowledge and support the organization’s
internal teams through design and delivery.
(c) Definition of strategy for internal and external
communication
Communication is vital to the success of a GAP in
delivering its objectives and should be a key element
defined in the corporate guidance.
Internal communication is important to ensure stake-
holder buy-in, awareness of GAP launches and
milestones, and education of any personnel likely to
be involved in a program and/or potentially receiving
requests for medication. Corporate guidance should
define the timeliness and content of training of
project, development, and commercial teams.
External communication of GAPs is a difficult area
and one where there is often much debate within
organizations around what is acceptable from a
regulatory viewpoint. It is important that corporate
guidance defines how the GAP will be communicated
externally, to ensure both regulatory compliance and
upfront agreement with internal stakeholders as to
acceptable communications. Particularly in the areas
of rare diseases and orphan drugs, there is also an
opportunity to work with patient advocacy groups and
organizations to ensure information is widely avail-
able through them.
(d) Assessment of pharmaceutical supply of the drug
A key element for consideration is the quantity of the
drug available. Whether the drug is clinical trial
material or a licensed pack from a territory with a
marketing authorization will impact both the geo-
graphical scope and regulatory assessment. It is
important to ensure that there is sufficient inventory
(or plans to replenish) in order to supply requests,
particularly for long-term treatments. Where there is a
limited inventory, it may be necessary to restrict
access either on a first-come-first-served basis or, for
example, on a patient-screening basis, to ensure that
those who are assessed to benefit most receive the
available medication. Any re-supplies for ongoing
and long-term treatment needs to be factored in to this
planning. Adequate supply-chain planning is one area
that is frequently overlooked in GAP feasibility
assessment.
(e) Planning of exit strategy
Another important consideration that may influence
the project scope is the exit strategy. Depending on the
type and duration of treatment and launch plans for the
product, this strategy will vary considerably between
programs and should be factored into planning at an
early stage. The situation in the EU for products
licensed via the centralized procedure is particularly
complex, with product approval and subsequent
launch often occurring many months apart [7]. This
should be factored in from the outset, coupled with
consideration that some regulatory mechanisms stipu-
late that a product provided within the context of a
GAP should be made available to the patient until the
product is commercially available and reimbursed
within the patient’s country, or provided free of charge
for the duration of the patient’s treatment. Since the
exit strategy will potentially be communicated to
prescribers, health authorities, and other interested
parties at the outset, it is difficult to change this
position once stated, so upfront planning for closure is
vital in the planning phase.
(f) Consideration of pricing strategy
Another key consideration for the organization is
whether they wish to provide the product free of
charge or if they wish to charge for access. This will
impact on the possible regulatory routes available and,
if the sponsor wishes to charge for access, may limit
the territory scope feasible (see Table 2). Sponsors are
often concerned about setting an appropriate price for
access through GAPs and care should be taken to
ensure that this does not compromise subsequent
pricing and reimbursement negotiations. For this
reason, a premium on the first planned launch price
is typically recommended.
(g) Assessment of data collection requirements
Whilst collection of efficacy data should not be the
drive of a GAP, some data may be collected through
the delivery of a GAP which reflects real-world data
regarding the use of the product outside of the
confines of a clinical trial. Consideration of what
information can be gathered during a GAP should be
made at the outset and may include, but not be limited
to, patient demographics, physician and institute
information, patient screening and eligibility, intend-
ed use, and follow-up/outcome data.
4 Regulatory Considerations
Health authorities around the world have recognized the
need to allow treatment with an unlicensed product for
patients suffering from serious or life-threatening condi-
tions where licensed alternatives are either unavailable or
unsuitable for the patient. In the EU, European Medicines
Agency guidelines and directives [8–10] provide the
regulatory framework for access to unlicensed medicines
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outside the context of the clinical trial. Although this EU
framework exists, each member state has defined inde-
pendently how and when to allow such access, and have
developed national rules and legislation to reflect this [11–
14]. As a result, regulations vary considerably from country
to country, with more than 100 different regulations across
the member states [5, 12, 13]. This is further compounded
for products that undergo centralized market authoriza-
tions, which results in a product being simultaneously ap-
proved in each member state, but commercially
unavailable in every country until the additional country-
specific requirements for labeling, pricing, reimbursement,
and launch are completed, further delaying patient access
to potentially life-saving treatments [7].
Given the complexity of the regulations, the regulatory
environment for the specific product should be assessed
during the initial planning phase for a GAP, and should
consider the following factors:
• license status of the product (completely unlicensed,
licensed in the country in question but not commer-
cially available, not licensed in the country in question
but licensed in another country, withdrawn); and
• patient population (ex-clinical trial patients, new
patients, patients not meeting eligibly criteria of
ongoing trials).
Assessment of the regulatory environment for a product
will, for example, identify countries where supply is not
possible or instances where more than one potential route for
access exists, requiring a choice between a single-patient or
cohort approach (Table 3). In these instances, the sponsor
may often have a preference on the regulatory route to use,
depending on other factors such as pricing structure, phar-
macovigilance capabilities in the country, product avail-
ability, and labeling and set-up times and costs (Table 2).
Other factors that may influence the feasibility in a
particular European country include product type (small
molecule, biological, blood product, etc.), country of
manufacture, licensed indication, and country of autho-
rization (if applicable).
In contrast to the EU, US regulations for unlicensed use
are described under US clinical trial legislation [2, 3]. As a
result, there is more overlap with traditional clinical trial
processes than elsewhere in the world, such as require-
ments for monitoring, safety data collection, reporting, and
site management, which places significant burden upon
both the pharmaceutical company and physician, and is
believed to be an important factor in explaining why the
numbers of patients accessing unlicensed medicines in the
USA is still relatively low [16, 17].
Table 2 Factors affecting decision on global access program type
Factors to consider Global access program type
Single-patient access Cohort access
Pricing structure Majority of countries allow charging for product, with
exceptions in the case of some investigational medical
products
Majority of cohort approaches mandate free-of-charge
product, with a commitment to ensuring supply until
product is commercially available in a patient’s
country
Pharmacovigilance Generally limited to spontaneous reporting by the
physician directly to the competent health authority
Often a requirement for monitoring or additional
reporting by sponsor company
Product availability and
labeling
English pack, labeled in accordance with guidance note
14 [15], is generally acceptable for an investigational
medicinal product. In the case that the product is
approved in another country, the licensed pack from
that country can be used
Often a requirement for a specifically labeled pack, in
local language
Set-up time and costs Generally, a program-wide approach can be
implemented across all countries, limiting the time
and resources needed
Additional time and resources to prepare country-
specific protocols, informed consent forms and
supporting information, and for subsequent
submission and approval
Table 3 Overview of single-patient and cohort access programs
Single-patient access Cohort access
Provision of controlled, pre-
approval access to a drug
before it is licensed and
commercially available in the
patient’s home country
Provision of controlled, pre-
approval access to a drug
before it is licensed and
commercially available in the
patient’s home country
A specific regulatory process is
defined in each country for
approval of access for a single
patient
A specific regulatory process is
defined in each country for
approval of access for cohorts
of patients
Individual access is initiated by a
patient’s physician
A program is defined for access
for a group of patients, initiated




Approval times can be lengthy
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Regulations across countries outside of the EU and USA
can vary widely and may often be ill-defined, particularly
in countries with limited pharmaceutical markets. In gen-
eral, only a few such countries permit a cohort approach,
whereas most of these countries allow single-patient access
routes. Single-patient access in these countries often relies
on personal importation by the patient or patient’s family,
or is limited to products that are already approved in a
major pharmaceutical market such as the USA, Japan, or
the EU.
5 Set-Up and Implementation of a GAP
Set-up and implementation activities fall into defined areas
and require specialist input, with centralized management
of the various functions involved. Some of the activities
that need to be considered are shown in Table 4.
6 Ongoing Management and Program Closure
Once the GAP is launched, ongoing management is re-
quired to ensure successful delivery. This will include
monitoring of stock levels, resolution of any issues, and, in
particular, management through key lifecycle milestones
such as approvals in the USA or EU, commercialization in
each country, extension to new countries, variations to drug
product used, changes in pricing strategy, and, of course,
the program exit strategy at its conclusion.
7 Conclusions
The initiation and management of a GAP can be chal-
lenging and requires careful assessment and planning. The
demand for a program often occurs at the very time com-
panies are focused on other activities such as the delivery
of pivotal clinical trials or gaining of marketing
authorization.
In order to be able to respond to requests for early access
in a timely manner, companies should plan to implement a
comprehensive strategy at a global level. This is par-
ticularly relevant for companies involved in the develop-
ment of products in areas of high unmet need, where there
is an absence of approved and commercially available al-
ternative treatments on the market.
The type and scope of the GAP that is run will depend
on considerations such as demand, regulatory feasibility,
the license status of the product, and necessary drug pricing
structure, as well as company strategy, costs, and product
supply. GAPs require careful and efficient planning and
management, from set-up to closure, by either an internal
coordinating project manager or by a specialist provider.
Well-run GAPs provide an ethical and regulatory-com-
pliant pathway for access to new treatments by patients
with serious conditions and unmet medical need, and en-
able the building of relationships with prescribers, allowing
Table 4 Set up and implementation activities
Area Set up and implementation activities
Process and
documentation
Preparation of information to be provided to
healthcare professionals relating to the GAP
and the product
Definition of patient population, eligibility
criteria, medical review processes, and how
these will be managed
Arrangement of compliant management
process for patient data and reporting, and
medical information enquiries
Quality and safety Management of product presentation, labeling,
and qualified person certification and release
(if applicable)
Adherence to company standard operating
procedures
Definition of process for managing
pharmacovigilance
Regulatory Communication with agencies, and preparation
of protocols, submissions, and timelines
Management of request for regulatory support
from healthcare professionals
Ongoing agency communication throughout
the program at product milestones
Supply chain and
logistics
Preparation of a logistics plan to consider
courier selection, in-country representation,
shipment conditions and frequency, and
import requirements of the product
Management of small, frequent, direct-to-site
shipments in appropriate turnaround times
Planning for any restrictions in stock




Decision on price to be charged for product
Consideration of impact of project milestones
on pricing and any requirement for ‘switches’
(e.g., products may initially be provided free
of charge until approved in a major market,
and then be transitioned to ‘paid for’), as well
as assessment of pricing impact on final
commercial price
Ongoing budget monitoring and control
Communication
and training
Agreement on required communication and
training, including press releases,
conferences, and electronic media
Engagement with patient advocacy groups and
organizations
Management of communication with sponsor
stakeholders
GAP global access program
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them to gain experience of using a drug before it becomes
commercially available.
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